An open label, two-part, phase Ib/II study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of the MEK inhibitor trametinib and the BCL-2-family inhibitor navitoclax (ABT-263) in combination in subjects with KRAS mutation-positive advanced solid tumors - Stand Up To Cancer

Blog

Posted October 14, 2019

An open label, two-part, phase Ib/II study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of the MEK inhibitor trametinib and the BCL-2-family inhibitor navitoclax (ABT-263) in combination in subjects with KRAS mutation-positive advanced solid tumors

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.